Diabetic Macular Edema
Conditions
Brief summary
Phase III clinical study to evaluate the efficacy, expressed as improvement in visual acuity in patients suffering diabetic macular edema after one year of treatment with PRO-169, compared to treatment with Lucentis® (ranibizumab).
Detailed description
A total of 442 patients with diabetic macular edema will be randomized 1:1 to be treated with either PRO-169 (bevacizumab) or Lucentis® (ranibizumab). There will be a total of 14 visits, including selection and final visits. Monthly evaluations will include ophthalmologic evaluations of anterior and posterior segments, as well as OCT (optic coherence tomography) to obtain central macular width and retinal volume. Fluorescein angiography will be performed on selection visit as well as 6 and 12 months into the study (visits 7 and 13). All patients will be exposed to intravitreal injection of either of the studied drugs monthly for the first 4 months. Starting on visit 5 patients will be injected depending on their response to treatment, calculated according predetermined algorithms including clinical and image variables. Starting on month 6, patients may be subjected to rescue therapy with photocoagulation if they comply with predetermined criteria for such measure.
Interventions
BIOLOGICALBevacizumab
Administration of monthly intravitreal bevacizumab (4-12 injections)
BIOLOGICALLucentis®
Administration of monthly intravitreal ranibizumab (4-12 injections)
Sponsors
Laboratorios Sophia S.A de C.V.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Intervention model description
Clinical study, phase III, multi-centric, randomized, double-blind, with active parallel control to show non-inferiority.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Diagnosis of Diabetes Mellitus (type 1 or 2) evidenced by: use of insulin or use of oral hypoglycemic medications or diagnosis for DM according to OMS or ADA criteria. * Is capable of rendering informed consent. * HbA1c \<8.5% in selection visit. * All men and women capable of reproduction may agree to use a barrier birth control method during the study and 3 months after the last intravitreal injection applied. * Only one eye may be randomized per participating individual, in case both are eligible, the investigator may choose either eye according his/her criteria. * BVCA according to ETDRS between \<78 (20/32 or worse) and \>24 (20/320 or better) within 8 days prior to the randomization. * Clinically evident diabetic macular edema, with central macular thickening. * Diabetic macular edema demonstrated in OCT scan (macular central thickness \> 300 μm for men and \> 290 μm for women) within 8 days prior to the randomization. * Presenting characteristics that allow an adequate fundus examination (transparent means, adequate pupil dilation, etc).
Exclusion criteria
* Chronic renal disease with renal insufficiency that requires dialysis or transplant. * Individuals with conditions that may compromise their participation during the span of the study (unstable concomitant diseases, possible change of residence, etc) * Individuals with a poor glycemic control who have started insulin treatment within 4 months previous to the study. * Participation in another clinical study (at least 90 days must have elapsed between the finalization of his/her participation in a previous essay and randomization in the present study). * Known allergies to the treatment. * Poorly controlled blood pressure (average of 3 readings while sitting with ≥160 mmHg systolic or ≥100 mmHg diastolic in the selection visit. * Heart attack or other cardiovascular event (cerebral vascular disease, transitory ischemia, hospitalization for cardiac insufficiency) during the 4 months prior to the start of the study, or patients with active myocardial insufficiency. * Previous systemic treatment with VEGF-related medications within 4 months prior to the start of the study. * Women of child-bearing age who are pregnant, lactating of planning to get pregnant within the time span of the study. * Known allergy to anesthetic medications used during the procedures, intravitreal injection and photocoagulation. * Diagnosis of non-diabetic macular edema. * Ophthalmic conditions that interfere with the evaluation of BCVA (for example: foveal atrophy, pigmentary abnormalities, dense foveal exudates, etc) * Additional conditions to DM that may compromise the evaluation of the edema (for example: venous occlusions, uveitis or other inflammatory diseases, neovascular glaucoma, etc) * Lens opacities that according to the LOCS III classification system exceed one or more of the following: \> NO3C3, \> C2, \> P1. * Previous history of anti-VEGF treatment for diabetic macular edema or any treatment for diabetic macular edema within 4 months prior to the start of the study (corticosteroids, photocoagulation, etc) * Anticipation of the need of panphotocoagulation (for example: proliferative diabetic retinopathy or any other indication) during the period of the study or history of panphotocoagulation within the 4 months prior to the start of the study. * History of ocular surgery (cataract extraction, any intraocular surgery, aphakia, etc) within 4 months prior to the start of the study, or planned to occur within the time span of the study. * Intraocular pressure \> 21 mmHg, measured through Goldmann tonometry during the selection visit. * Presence of macular ischemia or important loss of perifoveal capilaries (avascular foveal zone greater than 350 μm) demonstrated through fluorescein angiography during the selection visit. * Evidence of macular traction and hyaloid thickening in OCT scan. * History of YAG capsulotomy within 2 months prior to the randomization. * Evidence of external ocular infections or any important disease of the ocular surface. * History of vitrectomy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Best Corrected Visual Acuity | Day 30±3 (Visit 2), Day 60±3 (Visit 3), Day 90±3 (Visit 4), Day 120±3 (Visit 5), Day 150±3 (Visit 6), Day 180±3 (Visit 7), Day 210±3 (Visit 8), Day 240±3 (Visit 9), Day 270±3 (Visit 10), Day 300±3 (Visit 11), Day 330±3 (Visit 12), Day 360±3 (Final Visit) | Best Corrected Visual Acuity will be evaluated according the standardized ETDRS. The mean change between two treatments will be used evaluated as difference between baseline and final (12 months) values. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best Corrected Visual Acuity Area Under the Curve | Day 30±3 (Visit 2), Day 60±3 (Visit 3), Day 90±3 (Visit 4), Day 120±3 (Visit 5), Day 150±3 (Visit 6), Day 180±3 (Visit 7), Day 210±3 (Visit 8), Day 240±3 (Visit 9), Day 270±3 (Visit 10), Day 300±3 (Visit 11), Day 330±3 (Visit 12), Day 360±3 (Final Visit) | Best Corrected Visual Acuity will be evaluated according the standardized ETDRS. The area under the curve of both treatments will be used evaluated as difference between baseline and final (12 months) values. |
| Best Corrected Visual Acuity | Day 120±3 (Visit 5) | Best Corrected Visual Acuity will be evaluated according the standardized ETDRS. The corrected BCVA (adjusted to baseline value) of both treatments will be used evaluated at 4 months. The value was obtained from the value obtained on day 120 minus the baseline value. |
| Central Macular Thickness | Day 30±3 (Visit 2), Day 60±3 (Visit 3), Day 90±3 (Visit 4), Day 120±3 (Visit 5), Day 150±3 (Visit 6), Day 180±3 (Visit 7), Day 210±3 (Visit 8), Day 240±3 (Visit 9), Day 270±3 (Visit 10), Day 300±3 (Visit 11), Day 330±3 (Visit 12), Day 360±3 (Final Visit) | Central macular thickness will be evaluated through OCT scan. The mean change between two treatments will be used evaluated as difference between baseline and final (12 months) values. |
| Retinal Volume | Day 30±3 (Visit 2), 60±3 (Visit 3), 90±3 (Visit 4), 120±3 (Visit 5), 150±3 (Visit 6), 180±3 (Visit 7), 210±3 (Visit 8), 240±3 (Visit 9), 270±3 (Visit 10), 300±3 (Visit 11), 330±3 (Visit 12), 360±3 (Final Visit) | Retinal volume will be evaluated through OCT scan. The mean change between two treatments will be used evaluated as difference between baseline and final (12 months) values. |
| Percentage of Patients With a Positive Response to Treatment. | Day 120±3 (Visit 5), Day 150±3 (Visit 6), Day 180±3 (Visit 7), Day 210±3 (Visit 8), Day 240±3 (Visit 9), Day 270±3 (Visit 10), Day 300±3 (Visit 11), Day 330±3 (Visit 12), Day 360±3 (Final Visit) | Determining the percentage of patients with a positive response to treatment, considered as: absolute improvement (20/20 vision for two consecutive visits and central macular thickness \< 300 μm in men and \< 290 μm in women), improvement (one or more of the following: patient who gained 5 or more letters for BCVA, ≥ 10% decrease of macular central thickness value compared to last two visits) and stability (one or more of the following: patient with neither a gain of 5 or more letters for BCVA nor a ≥ 10% decrease of macular central thickness value compared to last two visits, patient without loss of 5 or more letters for BCVA or a ≥ 10% decrease of macular central thickness value compared to last visit). |
| Mean Number of Injections | Day 30±3 (Visit 2), Day 60±3 (Visit 3), Day 90±3 (Visit 4), Day 120±3 (Visit 5), Day 150±3 (Visit 6), Day 180±3 (Visit 7), Day 210±3 (Visit 8), Day 240±3 (Visit 9), Day 270±3 (Visit 10), Day 300±3 (Visit 11), Day 330±3 (Visit 12), Day 360±3 (Final Visit) | Determining the mean number of injections applied during study, comparing both arms. |
| Frequency of Rescue Therapy Administration | Day 30±3 (Visit 2), Day 60±3 (Visit 3), Day 90±3 (Visit 4), Day 120±3 (Visit 5), Day 150±3 (Visit 6), Day 180±3 (Visit 7), Day 210±3 (Visit 8), Day 240±3 (Visit 9), Day 270±3 (Visit 10), Day 300±3 (Visit 11), Day 330±3 (Visit 12), Day 360±3 (Final Visit) | Number of patients who required photocoagulation treatment |
| Adverse Events Related to the Injection | Day 360±3 (Final Visit) | This section describes the treatment-related adverse events reported throughout the study |
| Ophthalmic Drug-related Adverse Events | Day 360±3 (Final Visit) | The number of adverse events related to the eyes associated with the medication is described. |
| Systemic Drug-related Adverse Events | Day 360±3 (Final Visit) | The number of treatment-related adverse events at the systemic level is described |
Countries
Mexico
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 61.13 years STANDARD_DEVIATION 8.5 |
| Best-corrected visual acuity | 58.04 letters STANDARD_DEVIATION 13.4 |
| Best-corrected visual acuity (LogMAR) | 0.53 LogMAR STANDARD_DEVIATION 0.3 |
| BMI | 28.15 kg/m^2 STANDARD_DEVIATION 4.5 |
| Central macular thickness | 433.77 micrometers STANDARD_DEVIATION 118.4 |
| Central volume of the retina | 11.76 cubic millimeter STANDARD_DEVIATION 2.2 |
| Diabetes mellitus | 16.45 years STANDARD_DEVIATION 8.6 |
| Diabetic macular edema | 1.14 years STANDARD_DEVIATION 1.5 |
| HbA1c [%] | 7.28 percentage of HbA1c STANDARD_DEVIATION 0.9 |
| Intraocular pressure | 14.61 millimeters of mercury (mmHg) STANDARD_DEVIATION 2.1 |
| Race and Ethnicity Not Collected | 0 Participants |
| Sex: Female, Male Female | 96 Participants |
| Sex: Female, Male Male | 105 Participants |
| Waist circumference | 92.47 centimeters STANDARD_DEVIATION 13.5 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 2 / 255 | 3 / 254 |
| other Total, other adverse events | 114 / 255 | 103 / 254 |
| serious Total, serious adverse events | 2 / 255 | 3 / 254 |
Outcome results
None listed